Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseStatistically significant dose-dependent reduction in tumor volume across all treatment groups compared to control in an ovarian xenograft model. Complete elimination of tumor and